Important: Models were tasked with extracting evidence from documents. Some outputs may be low quality and should be scored accordingly.
Your task: Compare the model-generated prediction (right panel) against the ground truth criteria (left panel).
Evaluation scale (0-4):
Consider both content accuracy and completeness. Some predictions may be technically "correct" but incomplete or out of order.
INCLUSION CRITERIA 1. Any of the following hematologic malignancies:Acute myeloid leukemia (AML) in first cytomorphological remission (< 5% blasts in the bone marrow) with Disease Risk Index (DRI) intermediate or above, or in second or higher cytomorphological remissionAcute lymphoblastic leukemia (ALL) in first or higher remission (< 5% blasts in the bone marrow)Myelodysplastic syndrome (MDS): transfusion-dependent (requiring at least one transfusion per month), or intermediate or higher Revised International Prognostic Scoring System (IPSS-R) risk groupClinical justification of allogeneic stem cell transplantation where a suitable HLA matched sibling or unrelated donor is unavailable in a timely manner. 2. An unrelated donor search is not required for a patient to be eligible if the clinical situation dictates an urgent transplantation. 3. Clinical urgency is defined as 6-8 weeks from referral to transplant center or low likelihood of finding a matched unrelated donorAvailability of a related haploidentical donor with ≥ 4/8 but < 7/8, or ≥ 5/10 but < 9/10 matches at the HLA-A, -B, -C, -DRB1, and/or -DQB1 loci, as determined by high resolution human leukocyte antigen (HLA)-typingKarnofsky Performance Status (KPS) ≥ 70%Male or female, age ≥ 18 years and ≤ 70 years. 4. Patients aged ≥ 65 years must have a Sorror score ≤ 3Availability of a donor aged ≥ 16 years and ≤ 75 years who is eligible according to local requirements and regulationsFor females of childbearing potential who are sexually active and males who have sexual contact with a female of childbearing potential: willingness to use of reliable methods of contraception (oral contraceptives, intrauterine device, hormone implants, contraceptive injection or abstinence) during study participationGiven written informed consent (patient and donor) EXCLUSION CRITERIA 1. Availability of a suitable HLA-matched sibling or unrelated donor in a donor search 2. Prior allogeneic hematopoietic stem cell transplantation 3. Diffusing capacity for carbon monoxide (hemoglobin corrected DLCO) < 50% predicted 4. Left ventricular ejection fraction < 45% (evaluated by echocardiogram or MUGA scan) 5. Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 2.5 × upper limit of normal (CTCAE grade 2) 6. Bilirubin > 1.5 × upper limit of normal (CTCAE grade 2) 7. Creatinine clearance < 50 ml/min (calculated or measured) 8. Positive pregnancy test or breastfeeding of patient or donor (women of childbearing age only) 9. Estimated probability of surviving less than 3 months 10. Known allergy to any of the components of ATIR101 (e.g., dimethyl sulfoxide) 11. Known hypersensitivity to cyclophosphamide or any of its metabolites 12. Any contraindication for GVHD prophylaxis with mycophenolate mofetil, cyclosporine A, or tacrolimus 13. Known presence of HLA antibodies against the non-shared donor haplotype 14. Positive human immunodeficiency virus (HIV) test 15. Positive viral test of the donor for HIV-1, HIV-2, hepatitis B virus (HBV), hepatitis C virus (HCV), Treponema pallidum, human T-lymphotropic virus (HTLV) 1 (if tested), HTLV-2 (if tested), West Nile virus (WNV; if tested), or Zika virus (if tested) 16. Any other condition that, in the opinion of the investigator, makes the patient or donor ineligible for the study
Modified Eligibility Criteria for Version 4 of Clinical Trial Protocol CR-AIR-009 Based on the provided text from the protocol, here are the modified eligibility criteria for Version 4 of the CR-AIR-009 clinical trial, incorporating the evidence and considerations from the protocol: INCLUSION CRITERIA 1. Hematologic Malignancy: 2. Acute myeloid leukemia (AML) in first cytomorphological remission with Disease Risk Index (DRI) intermediate or above, or in second or higher cytomorphological remission. 3. Acute lymphoblastic leukemia (ALL) in first or higher remission. 4. Myelodysplastic syndromes (MDS) requiring transfusion-dependent treatment (requiring at least one transfusion per month) or intermediate or higher Revised International Prognostic Scoring System (IPSS-R) risk group. 5. Age: 18 years or older. 6. Karnofsky Performance Status (KPS): ≥ 70%. 7. Transplantation Eligibility: 8. Availability of a suitable haploidentical donor (HLA-matched sibling or unrelated donor) with ≥ 4/8 HLA matching at the HLA-A, -B, -C, -DRB1, and -DQB1 loci. 9. A donor match of ≥ 4/8 HLA matching is required for haploidentical HSCT. 10. A donor match of ≥ 5/8 HLA matching is required for haploidentical HSCT with post-transplant cyclophosphamide. 11. Other Considerations: 12. Patients aged ≥ 65 years must have a Sorror score ≤ 3. 13. Females of childbearing potential must use reliable methods of contraception during study participation. 14. Males with sexual contact with a female of childbearing potential must use reliable methods of contraception. EXCLUSION CRITERIA 1. Previous allogeneic hematopoietic stem cell transplantation (HSCT). 2. Left ventricular ejection fraction (LVEF) < 50% (evaluated by echocardiogram or MUGA). 3. Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 2.5 × upper limit of normal (ULN). 4. Creatinine clearance < 50 ml/min. 5. Positive pregnancy test. 6. Known allergy to any component of ATIR101. 7. History of hypersensitivity to cyclophosphamide or any of its metabolites. 8. Presence of HLA antibodies against the non-shared donor haplotype. 9. Other conditions that, in the opinion of the investigator, make the patient ineligible for the study. 10. Important Notes: 11. Version 4 Considerations: The provided text does not explicitly state the specific changes from Version 3. However, the INCLUSION CRITERIA 1. have been updated to reflect the current understanding of the study population and the inclusion of specific age and performance status criteria. 2. Specifics: The exact wording of the inclusion and EXCLUSION CRITERIA 1. may vary depending on the specific version of the protocol. 2. Clinical Relevance: The inclusion and EXCLUSION CRITERIA 1. are crucial for ensuring the safety and efficacy of the study. They help to select patients who are most likely to benefit from the treatment and minimize the risk of adverse events. 2. Further Information:** For a complete understanding of the eligibility criteria, it is essential to refer to the full protocol document.